Teva’s U.S. Generic Sales Rebound With Late-Year Launches, Ranbaxy Lipitor Deal
By
Sue Sutter / Email the Author / “The Pink Sheet” DAILY Feb. 16, 2012
Word Count: 693 / Article # 14120216003
Executive Summary
The Israel-based manufacturer saw its full-year U.S. generic revenues drop 32% due to expired marketing exclusivities and manufacturing problems at two plants. However, the fourth quarter brought a rebound, thanks to launches of generic Zyprexa and Combivir and a profit-sharing agreement on atorvastatin.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.